Patent intelligence · US
US 6305380
Method for treatment of cancer and infectious disease
Method for treatment of cancer and infectious disease
Patent details — US 6305380
- Jurisdiction
- US
- Status
- expired
- Grant date
- Oct 23, 2001
- Expiration
- Oct 18, 2021
- Applicant
- Maxim Pharmaceuticals, Inc.
- Claims
- 18
- CPC classes
- A61K, A61K38/212, A61K45/06, A61P
Quick answer
US 6305380 (Method for treatment of cancer and infectious disease) is held by Maxim Pharmaceuticals, Inc.. Status: expired. Granted Oct 23, 2001. Expires Oct 18, 2021 (0 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Maxim Pharmaceuticals, Inc.
- Grant date
- Expiration
- Claims
- 18
- CPC classes
- A61K, A61K38/212, A61K45/06, A61P, A61P31/12
More from Maxim Pharmaceuticals, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12391732
Articles comprising a silk polypeptide for antigen delivery
granted -
US 12379385
Methods of treating patients afflicted with irritable bowel syndrome, inflammatory bowel disease or chronic gastrointestinal functional disorders based on assessment of intestinal barrier function
granted -
US 12318397
Methods and compositions for testosterone production
granted -
US 12290524
Methods and compositions for testosterone production
granted -
US 12171837
Chemoselective thiol-conjugation with alkene or alkyne-phosphonamidates
granted -
US 12168718
Thermogelling supramolecular sponge as self-healing and biocompatible hydrogel
granted -
US 12144876
Security mechanisms for radiopharmaceutical elution system and elution process
granted -
US 12133890
Antigen-binding polypeptide targeting B7H3 and application thereof
granted
Frequently asked questions
What is US patent 6305380?
US 6305380 (Method for treatment of cancer and infectious disease) is held by Maxim Pharmaceuticals, Inc.. Status: expired. Granted Oct 23, 2001. Expires Oct 18, 2021 (0 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 6305380?
Maxim Pharmaceuticals, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 138 pharmaceutical patents for this assignee.
When does US 6305380 expire?
Our index shows an expiration date of Oct 18, 2021 (0 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.